BR112014012590A2 - anticorpos anti-cd98 e métodos de uso dos mesmos - Google Patents
anticorpos anti-cd98 e métodos de uso dos mesmosInfo
- Publication number
- BR112014012590A2 BR112014012590A2 BR112014012590A BR112014012590A BR112014012590A2 BR 112014012590 A2 BR112014012590 A2 BR 112014012590A2 BR 112014012590 A BR112014012590 A BR 112014012590A BR 112014012590 A BR112014012590 A BR 112014012590A BR 112014012590 A2 BR112014012590 A2 BR 112014012590A2
- Authority
- BR
- Brazil
- Prior art keywords
- antibodies
- methods
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161563443P | 2011-11-23 | 2011-11-23 | |
| PCT/US2012/066347 WO2013078377A1 (en) | 2011-11-23 | 2012-11-21 | Anti-cd98 antibodies and methods of use thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BR112014012590A2 true BR112014012590A2 (pt) | 2017-06-20 |
| BR112014012590A8 BR112014012590A8 (pt) | 2017-12-19 |
Family
ID=47295209
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112014012590A BR112014012590A8 (pt) | 2011-11-23 | 2012-11-21 | Anticorpos anti-cd98 e métodos de uso dos mesmos |
Country Status (15)
| Country | Link |
|---|---|
| EP (1) | EP2782935A1 (pt) |
| JP (1) | JP2015501639A (pt) |
| KR (1) | KR20140125351A (pt) |
| CN (1) | CN104302669A (pt) |
| AU (1) | AU2012340623A1 (pt) |
| BR (1) | BR112014012590A8 (pt) |
| CA (1) | CA2856873A1 (pt) |
| HK (1) | HK1202877A1 (pt) |
| IL (1) | IL232755A0 (pt) |
| MX (1) | MX2014006272A (pt) |
| PH (1) | PH12014501164A1 (pt) |
| RU (1) | RU2014124530A (pt) |
| SG (1) | SG11201402619VA (pt) |
| WO (1) | WO2013078377A1 (pt) |
| ZA (1) | ZA201403760B (pt) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012097313A2 (en) | 2011-01-14 | 2012-07-19 | The Regents Of The University Of California | Therapeutic antibodies against ror-1 protein and methods for use of same |
| WO2014197866A1 (en) | 2013-06-06 | 2014-12-11 | Igenica Biotherapeutics, Inc. | Modified antibodies and related compounds, compositions, and methods of use |
| US20140363454A1 (en) * | 2013-06-06 | 2014-12-11 | Igenica Biotherapeutics, Inc. | Antibody-Drug Conjugates, Compositions and Methods of Use |
| JP2017114763A (ja) * | 2014-03-26 | 2017-06-29 | 第一三共株式会社 | 抗ｃｄ９８抗体−薬物コンジュゲート |
| RU2017120039A (ru) * | 2014-12-10 | 2019-01-10 | Дженентек, Инк. | Антитела к рецепторам гематоэнцефалического барьера и способы их применения |
| SI3336185T1 (sl) * | 2015-08-10 | 2022-04-29 | Osaka University | Protitelo |
| CN105385694B (zh) * | 2015-11-20 | 2019-01-18 | 中国人民解放军第四军医大学 | 抗人cd98单克隆抗体98-3h3轻、重链可变区基因及其应用 |
| EP3468599A2 (en) * | 2016-06-08 | 2019-04-17 | AbbVie Inc. | Anti-cd98 antibodies and antibody drug conjugates |
| WO2017214335A1 (en) | 2016-06-08 | 2017-12-14 | Abbvie Inc. | Anti-b7-h3 antibodies and antibody drug conjugates |
| CN109562170B (zh) * | 2016-06-08 | 2023-01-13 | 艾伯维公司 | 抗cd98抗体及抗体药物偶联物 |
| WO2017214456A1 (en) * | 2016-06-08 | 2017-12-14 | Abbvie Inc. | Anti-cd98 antibodies and antibody drug conjugates |
| EP3749373A1 (en) | 2018-02-07 | 2020-12-16 | Regeneron Pharmaceuticals, Inc. | Methods and compositions for therapeutic protein delivery |
| EP3715370A1 (en) * | 2019-03-28 | 2020-09-30 | Technische Universität München | High affinity anticalins directed against human cd98hc |
| MX2022012633A (es) * | 2020-04-08 | 2023-01-11 | Aliada Therapeutics Inc | Anticuerpos anti-cd98, y usos de los mismos. |
| UY39610A (es) | 2021-01-20 | 2022-08-31 | Abbvie Inc | Conjugados anticuerpo-fármaco anti-egfr |
| CN117561276A (zh) * | 2021-06-02 | 2024-02-13 | 华辉安健（北京）生物科技有限公司 | 抗cd98抗体及其应用 |
| WO2023109956A1 (en) * | 2021-12-17 | 2023-06-22 | Biocytogen Jiangsu Co., Ltd. | Genetically modified non-human animal with human or chimeric cd98hc |
Family Cites Families (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3720760A (en) | 1968-09-06 | 1973-03-13 | Pharmacia Ab | Method for determining the presence of reagin-immunoglobulins(reagin-ig)directed against certain allergens,in aqueous samples |
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
| US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
| NZ207394A (en) | 1983-03-08 | 1987-03-06 | Commw Serum Lab Commission | Detecting or determining sequence of amino acids |
| US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
| US4737456A (en) | 1985-05-09 | 1988-04-12 | Syntex (U.S.A.) Inc. | Reducing interference in ligand-receptor binding assays |
| DE3675588D1 (de) | 1985-06-19 | 1990-12-20 | Ajinomoto Kk | Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist. |
| US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US5260203A (en) | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| ATE120761T1 (de) | 1987-05-21 | 1995-04-15 | Creative Biomolecules Inc | Multifunktionelle proteine mit vorbestimmter zielsetzung. |
| US5258498A (en) | 1987-05-21 | 1993-11-02 | Creative Biomolecules, Inc. | Polypeptide linkers for production of biosynthetic proteins |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| ES2113940T3 (es) | 1990-12-03 | 1998-05-16 | Genentech Inc | Metodo de enriquecimiento para variantes de proteinas con propiedades de union alteradas. |
| US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| ES2206447T3 (es) | 1991-06-14 | 2004-05-16 | Genentech, Inc. | Anticuerpo humanizado para heregulina. |
| DK0605522T3 (da) | 1991-09-23 | 2000-01-17 | Medical Res Council | Fremgangsmåde til fremstilling af humaniserede antistoffer |
| ES2136092T3 (es) | 1991-09-23 | 1999-11-16 | Medical Res Council | Procedimientos para la produccion de anticuerpos humanizados. |
| US5587458A (en) | 1991-10-07 | 1996-12-24 | Aronex Pharmaceuticals, Inc. | Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof |
| NL9101953A (nl) | 1991-11-21 | 1993-06-16 | Seed Capital Investments | Testinrichting omvattende een plaat met een veelvoud van putjes met een bijbehorende doseerinrichting, alsmede een kit die deze inrichtingen omvat en toepassing van de inrichtingen. |
| JPH07501451A (ja) | 1991-11-25 | 1995-02-16 | エンゾン・インコーポレイテッド | 多価抗原結合タンパク質 |
| AU675929B2 (en) | 1992-02-06 | 1997-02-27 | Curis, Inc. | Biosynthetic binding protein for cancer marker |
| ZA932522B (en) | 1992-04-10 | 1993-12-20 | Res Dev Foundation | Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens |
| GB9225453D0 (en) | 1992-12-04 | 1993-01-27 | Medical Res Council | Binding proteins |
| JP3720353B2 (ja) | 1992-12-04 | 2005-11-24 | メディカル リサーチ カウンシル | 多価および多重特異性の結合タンパク質、それらの製造および使用 |
| US5827690A (en) | 1993-12-20 | 1998-10-27 | Genzyme Transgenics Corporatiion | Transgenic production of antibodies in milk |
| US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
| US5739277A (en) | 1995-04-14 | 1998-04-14 | Genentech Inc. | Altered polypeptides with increased half-life |
| GB9701425D0 (en) | 1997-01-24 | 1997-03-12 | Bioinvent Int Ab | A method for in vitro molecular evolution of protein function |
| US5994071A (en) | 1997-04-04 | 1999-11-30 | Albany Medical College | Assessment of prostate cancer |
| US6602677B1 (en) | 1997-09-19 | 2003-08-05 | Promega Corporation | Thermostable luciferases and methods of production |
| ATE375365T1 (de) | 1998-04-02 | 2007-10-15 | Genentech Inc | Antikörper varianten und fragmente davon |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| US7183387B1 (en) | 1999-01-15 | 2007-02-27 | Genentech, Inc. | Polypeptide variants with altered effector function |
| HUP0104865A3 (en) | 1999-01-15 | 2004-07-28 | Genentech Inc | Polypeptide variants with altered effector function |
| EP1197755A1 (en) | 2000-10-11 | 2002-04-17 | Pepscan Systems B.V. | Identification of protein binding sites |
| EP1438400B1 (en) | 2001-10-01 | 2009-06-17 | Dyax Corp. | Multi-chain eukaryotic display vectors and uses thereof |
| WO2003035842A2 (en) | 2001-10-24 | 2003-05-01 | Dyax Corporation | Hybridization control of sequence variation |
| EP1513879B1 (en) | 2002-06-03 | 2018-08-22 | Genentech, Inc. | Synthetic antibody phage libraries |
| WO2005044853A2 (en) | 2003-11-01 | 2005-05-19 | Genentech, Inc. | Anti-vegf antibodies |
| EP1791565B1 (en) | 2004-09-23 | 2016-04-20 | Genentech, Inc. | Cysteine engineered antibodies and conjugates |
| US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| EA019983B1 (ru) | 2005-10-07 | 2014-07-30 | Экселиксис, Инк. | Ингибиторы mek и способы их применения |
| TWI390034B (zh) * | 2006-04-06 | 2013-03-21 | Kyowa Hakko Kirin Co Ltd | Novel anti-CD98 antibody |
| GB0615662D0 (en) * | 2006-08-07 | 2006-09-13 | Affitech As | Antibody |
| JPWO2011118804A1 (ja) * | 2010-03-26 | 2013-07-04 | 国立大学法人徳島大学 | 新規抗ｃｄ９８抗体とその用途 |
-
2012
- 2012-11-21 SG SG11201402619VA patent/SG11201402619VA/en unknown
- 2012-11-21 CA CA2856873A patent/CA2856873A1/en not_active Abandoned
- 2012-11-21 RU RU2014124530/10A patent/RU2014124530A/ru not_active Application Discontinuation
- 2012-11-21 MX MX2014006272A patent/MX2014006272A/es unknown
- 2012-11-21 KR KR1020147016959A patent/KR20140125351A/ko not_active Application Discontinuation
- 2012-11-21 WO PCT/US2012/066347 patent/WO2013078377A1/en active Application Filing
- 2012-11-21 EP EP12795978.1A patent/EP2782935A1/en not_active Withdrawn
- 2012-11-21 BR BR112014012590A patent/BR112014012590A8/pt not_active IP Right Cessation
- 2012-11-21 AU AU2012340623A patent/AU2012340623A1/en not_active Abandoned
- 2012-11-21 CN CN201280067876.7A patent/CN104302669A/zh active Pending
- 2012-11-21 JP JP2014543574A patent/JP2015501639A/ja active Pending
-
2014
- 2014-05-22 IL IL232755A patent/IL232755A0/en unknown
- 2014-05-22 ZA ZA2014/03760A patent/ZA201403760B/en unknown
- 2014-05-23 PH PH12014501164A patent/PH12014501164A1/en unknown
-
2015
- 2015-03-31 HK HK15103289.7A patent/HK1202877A1/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2012340623A1 (en) | 2014-07-17 |
| RU2014124530A (ru) | 2015-12-27 |
| EP2782935A1 (en) | 2014-10-01 |
| JP2015501639A (ja) | 2015-01-19 |
| PH12014501164A1 (en) | 2014-10-20 |
| KR20140125351A (ko) | 2014-10-28 |
| IL232755A0 (en) | 2014-07-31 |
| ZA201403760B (en) | 2017-09-27 |
| BR112014012590A8 (pt) | 2017-12-19 |
| NZ626513A (en) | 2017-02-24 |
| WO2013078377A9 (en) | 2013-08-08 |
| CN104302669A (zh) | 2015-01-21 |
| MX2014006272A (es) | 2014-10-24 |
| HK1202877A1 (en) | 2015-10-09 |
| WO2013078377A1 (en) | 2013-05-30 |
| CA2856873A1 (en) | 2013-05-30 |
| SG11201402619VA (en) | 2014-10-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112014012590A2 (pt) | anticorpos anti-cd98 e métodos de uso dos mesmos | |
| CO7020870A2 (es) | Anticuerpos anti-htra1 y métodos de uso | |
| BR112013017980A2 (pt) | polipeptídeos de imunoglobulina marcado com aldeído e método de uso dos mesmos | |
| BR112014028366A2 (pt) | anticorpos anti-ly6e e imunoconjugados e métodos de uso | |
| CL2016001556A1 (es) | Anticuerpos anti-cd3 y métodos de uso | |
| CL2014002086A1 (es) | Anticuerpos cd47 y métodos de uso los mismos | |
| BR112014002716A2 (pt) | anticorpos anti-poliubiquitina e métodos de uso | |
| CO6870033A2 (es) | Compuestos terapéuticos y métodos de uso relacionados | |
| CO7000747A2 (es) | Anticuerpos anti-lrp5 y métodos de uso | |
| CL2015001266A1 (es) | Anticuerpos de antihemaglutinina y métodos de uso. | |
| BR112014018136A2 (pt) | anticorpos ou uso e método para determinar | |
| BR112012024120A2 (pt) | sarms e método de uso dos mesmos | |
| BRPI1014544A8 (pt) | anticorpos anti-il-17f e metodos de uso dos mesmos | |
| BR112013014119A2 (pt) | novos moduladores e métodos de uso | |
| CO6821892A2 (es) | Anticuerpos anti-angptl3 y usos de los mismos | |
| CL2015000640A1 (es) | Variantes de hppd y métodos de uso | |
| BR112014012137A2 (pt) | anticorpos anti-fgfr2 e suas utilizações | |
| BR112013026410A2 (pt) | compostos antimicrobianos e métodos de preparação e uso dos mesmos | |
| CO6801741A2 (es) | Derivados c4-monometil triterpenoides y sus métodos de uso | |
| CO6870005A2 (es) | Composición anti-cgrp y uso de las mismas | |
| BR112013025353A2 (pt) | combinações de compostos de inibidores de akt e erlotinibe e métodos de uso | |
| BR112014009006A2 (pt) | compostos heterocíclicos e métodos de uso dos mesmos | |
| CO6801774A2 (es) | Compuestos de benzotiazol y su uso farmacéutico | |
| CO6862148A2 (es) | Composiciones transdérmicas de ibuprofeno y métodos de uso de las mismas | |
| BR112014002219A2 (pt) | conjugados anticorpo p97 e métodos de sua utilização |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B25D | Requested change of name of applicant approved |
Owner name: IGENICA BIOTHERAPEUTICS, INC. (US) |
|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 6A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2494 DE 23-10-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |